- Home
- OPCH vs ABCL Comparison
OPCH vs ABCL Comparison
Compare OPCH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | ABCL |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.1B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPCH | ABCL |
|---|---|---|
| Price | $31.66 | $12.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $30.03 | $18.00 |
| AVG Volume (30 Days) | 3.2M | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 10.91 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $4,998,202,000.00 | $75,128,000.00 |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | $6.41 | $16.61 |
| P/E Ratio | $31.02 | ★ N/A |
| Revenue Growth | 16.17 | ★ 160.56 |
| 52 Week Low | $18.01 | $2.75 |
| 52 Week High | $36.80 | $14.98 |
Technical Indicators
Market Signals| Indicator | OPCH | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 75.70 | 49.14 |
| Support Level | $28.70 | $11.78 |
| Resistance Level | $31.90 | $13.21 |
| Average True Range (ATR) | 0.16 | 0.98 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 61.76 | 43.23 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.